Key result
Multimodality cardiac imaging differentiates HCM from cardiac amyloidosis using distinct anatomical and tissue biomarkers.
Why the study?
Differentiating HCM from CA is clinically crucial because management strategies and prognostic implications differ substantially, yet overlapping phenotypic features such as left ventricular hypertrophy frequently complicate diagnosis.
This review highlights the critical role of multimodality imaging, including echocardiography and CMR, in differentiating hypertrophic cardiomyopathy from cardiac amyloidosis to guide appropriate management.
No takes yet. Share an insight, caveat, or question.
Enables targeted therapy for amyloidosis mimicking HCM; reinforces multimodality imaging value in ambiguous hypertrophy.
Maggialetti et al. (2026) conducted a review in Hypertrophic cardiomyopathy and cardiac amyloidosis. Multimodality cardiac imaging (Echocardiography, CMR, Nuclear imaging) was evaluated. Multimodality cardiac imaging, including echocardiography, CMR, and nuclear imaging, provides distinct anatomical and tissue characterization biomarkers to differentiate HCM from cardiac amyloidosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: